The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease

Langholz, 2010, Review: current trends in inflammatory bowel disease: the natural history, Ther Adv Gastroentrol, 3, 77, 10.1177/1756283X10361304 de Lima-Karagiannis, 2016, The effects of active IBD during pregnancy in the era of novel IBD therapies, Am J Gastroenterol, 111, 1, 10.1038/ajg.2016.254 Kammerlander, 2017, The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease, Inflamm Bowel Dis, 23, 1011, 10.1097/MIB.0000000000001102 Bröms, 2014, Birth outcomes in women with inflammatory bowel disease, Inflamm Bowel Dis, 20, 1, 10.1097/MIB.0000000000000060 Howson, 2013, Born too soon: preterm birth matters, Reprod Health, 10, S1, 10.1186/1742-4755-10-S1-S1 Frolkis, 2013, Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies, Gastroenterology, 145, 996, 10.1053/j.gastro.2013.07.041 Allez, 2010, Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects, J Crohn’s Colitis, 4, 355, 10.1016/j.crohns.2010.04.004 Katsanos, 2018, Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies, Clin Immunol McLean, 2014, Adverse events in IBD: to stop or continue immune suppressant and biologic treatment, Expet Rev Gastroenterol Hepatol, 8, 223, 10.1586/17474124.2014.881715 Picardo, 2019, A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: biologic and oral small molecule therapy, Drugs, 79, 1053, 10.1007/s40265-019-01141-w Chaparro, 2018, Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study, Am J Gastroenterol, 10.1038/ajg.2017.501 Anger, 2011, Pharmacokinetics in pregnancy, Reprod Dev Toxicol, 15, 39, 10.1016/B978-0-12-382032-7.10004-9 Feghali, 2015, Pharmacokinetics of drugs in pregnancy, Semin Perinatol, 39, 512, 10.1053/j.semperi.2015.08.003 Papamichael, 2019, Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?, Curr Opin Gastroenterol, 10.1097/MOG.0000000000000536 Yanai, 2015, Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab, Clin Gastroenterol Hepatol, 13, 522, 10.1016/j.cgh.2014.07.029 Khan, 2019, New Zealand society of Gastroenterology guidelines on therapeutic drug monitoring in inflammatory bowel disease, N Z Med J, 132, 46 Mitrev, 2017, Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases, Aliment Pharmacol Ther, 46, 1037, 10.1111/apt.14368 Vande Casteele, 2017, American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases, Gastroenterology, 153, 835, 10.1053/j.gastro.2017.07.031 Torres, 2020, ECCO guidelines on therapeutics in Crohn’s disease: medical treatment, J Crohn’s Colitis, 14, 4, 10.1093/ecco-jcc/jjz180 Vande Casteele, 2015, Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease, Gastroenterology, 148, 1320, 10.1053/j.gastro.2015.02.031 D’Haens, 2018, Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease, Gastroenterology, 154, 1343, 10.1053/j.gastro.2018.01.004 Tabrizi, 2006, Elimination mechanisms of therapeutic monoclonal antibodies, Drug Discov Today, 11, 81, 10.1016/S1359-6446(05)03638-X Deng, 2012, Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?, Expet Opin Drug Metabol Toxicol, 8, 141, 10.1517/17425255.2012.643868 Stone, 2014, Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women, J Clin Toxicol, 4 Keizer, 2010, Clinical pharmacokinetics of therapeutic monoclonal antibodies, Clin Pharmacokinet, 49, 493, 10.2165/11531280-000000000-00000 Frederiksen, 2001, Physiologic changes in pregnancy and their effect on drug disposition, Semin Perinatol, 25, 120, 10.1053/sper.2001.24565 Ternant, 2008, Infliximab pharmacokinetics in inflammatory bowel disease patients, Ther Drug Monit, 30, 523, 10.1097/FTD.0b013e318180e300 Palmeira, 2012, IgG placental transfer in healthy and pathological pregnancies, Clin Dev Immunol, 2012, 10.1155/2012/985646 Malek, 1998, Transport of proteins across the human placenta, Am J Reprod Immunol, 40, 347, 10.1111/j.1600-0897.1998.tb00064.x Porter, 2016, Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer, J Reprod Immunol, 116, 7, 10.1016/j.jri.2016.04.284 Kane, 2009, Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy, Am J Gastroenterol, 104, 228, 10.1038/ajg.2008.71 Junghans, 1996, The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor, Proc Natl Acad Sci U S A, 10.1073/pnas.93.11.5512 Knight, 1993, Construction and initial characterization of a mouse-human chimeric anti-TNF antibody, Mol Immunol, 30, 1443, 10.1016/0161-5890(93)90106-L Seow, 2017, The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease, Aliment Pharmacol Ther, 45, 1329, 10.1111/apt.14040 Kanis, 2018, Anti-TNF levels in cord blood at birth are associated with anti-TNF type, J Crohn’s Colitis, 10.1093/ecco-jcc/jjy058 Flanagan, 2019, P660 Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD, J Crohn’s Colitis, 13, S449, 10.1093/ecco-jcc/jjy222.784 Mahadevan, 2013, Placental transfer of anti-tumor necrosis factor Agents in pregnant patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, 10.1016/j.cgh.2012.11.011 Julsgaard, 2016, Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection, Gastroenterology, 151, 110, 10.1053/j.gastro.2016.04.002 Mahadevan, 2012, 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy, Gastroenterology, 142, 10.1016/S0016-5085(12)60561-7 Lichtenstein, 2012, Serious infection and mortality in patients with Crohnʼs disease: more than 5 Years of follow-up in the TREATTM registry, Am J Gastroenterol, 107, 1409, 10.1038/ajg.2012.218 Deepak, 2014, Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease, Aliment Pharmacol Ther, 40, 1035, 10.1111/apt.12936 Schnitzler, 2011, Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy, Inflamm Bowel Dis, 17, 1846, 10.1002/ibd.21583 Seirafi, 2014, Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease, Aliment Pharmacol Ther, 40, 363, 10.1111/apt.12833 Shihab, 2016, Anti-Tumour necrosis factor α therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis, J Crohns Colitis, 10, 979, 10.1093/ecco-jcc/jjv234 Narula, 2014, Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis, Inflamm Bowel Dis, 20, 1862, 10.1097/MIB.0000000000000092 van der Woude, 2015, The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease, J Crohns Colitis, 9, 107, 10.1093/ecco-jcc/jju006 Vande Casteele, 2013, Antibody response to infliximab and its impact on pharmacokinetics can be transient, Am J Gastroenterol, 108, 962, 10.1038/ajg.2013.12 Nguyen, 2016, The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy, Gastroenterology, 150, 734, 10.1053/j.gastro.2015.12.003 Beaulieu, 2018, Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines, Clin Gastroenterol Hepatol, 16, 99, 10.1016/j.cgh.2017.08.041 Heller, 2011, Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab, J Am Acad Dermatol, 65, 870, 10.1016/j.jaad.2011.04.030 van der Woude, 2015, The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease, J Crohn’s Colitis, 9, 107, 10.1093/ecco-jcc/jju006 Mahadevan, 2011, The london position statement of the world congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organisation: pregnancy and pediatrics, Am J Gastroenterol, 106, 214, 10.1038/ajg.2010.464 Guidi, 2011, Update on the management of inflammatory bowel disease: specific role of adalimumab, Clin Exp Gastroenterol, 4, 163, 10.2147/CEG.S14558 Mahadevan, 2013, Placental transfer of anti–tumor necrosis factor Agents in pregnant patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, 11, 286, 10.1016/j.cgh.2012.11.011 Johnson, 2009, Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project, Gastroenterology, 56, AB10 Carter, 2009, A safety assessment of tumor necrosis factor Antagonists during pregnancy: a review of the food and drug administration database, J Rheumatol, 36, 635, 10.3899/jrheum.080545 Vande Casteele, 2017, Therapeutic drug monitoring of golimumab in the treatment of ulcerative colitis, Pharm Res (N Y), 34, 1556, 10.1007/s11095-017-2150-2 Benoit, 2018, Treating ulcerative colitis during pregnancy: evidence of materno–fetal transfer of golimumab, J Crohn’s Colitis Mariette, 2018, Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study, Ann Rheum Dis, 10.1136/annrheumdis-2017-212196 Clowse, 2018, Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database, Arthritis Rheum, 70, 1399, 10.1002/art.40508 Park, 2018, Anti-integrin therapy for inflammatory bowel disease, World J Gastroenterol, 24, 1868, 10.3748/wjg.v24.i17.1868 Julsgaard, 2018, Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease, Aliment Pharmacol Ther, 48, 386, 10.1111/apt.14837 Mahadevan, 2017, Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease, Aliment Pharmacol Ther, 10.1111/apt.13960 Shim, 2017, Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?, Aliment Pharmacol Ther, 45, 1283, 10.1111/apt.14027 Bar-Gil Shitrit, 2019, Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate, Am J Gastroenterol, 114, 1172, 10.14309/ajg.0000000000000186 Moens, 2019, Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab, J Crohn’s Colitis, 13, 12, 10.1093/ecco-jcc/jjy142 Moens, 2020, Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study, Aliment Pharmacol Ther, 51, 129, 10.1111/apt.15539 Ward, 2018, Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions, Ther Adv Gastroentrol, 11 Mahadevan, 2016, 437 do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry, Gastroenterology, 10.1016/S0016-5085(16)30422-X Flanagan, 2018, Letter: vedolizumab drug concentrations in neonates following intrauterine exposure, Aliment Pharmacol Ther, 48, 1328, 10.1111/apt.15027 Sandborn, 2008, A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease, Gastroenterology, 135, 1130, 10.1053/j.gastro.2008.07.014 Adedokun, 2018, Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease, Gastroenterology, 10.1053/j.gastro.2018.01.043 Klenske, 2019, Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn’s disease, J Crohn’s Colitis, 13, 267, 10.1093/ecco-jcc/jjy153 Scherl, 2018, A109 pregnancy outcomes IN women exposed to ustekinumab IN the CROHN’S disease clinical development program, J Can Assoc Gastroenterol, 10.1093/jcag/gwy009.109 Watson, 2019, Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies, Br J Dermatol, 180, 195, 10.1111/bjd.17086